Japan Patent Office to Grant Patent Covering Dicerna RNAi Constructs | GenomeWeb

Dicerna Pharmaceuticals announced this week that the Japan Patent Office has said it intends to grant a patent on an application covering Dicer-substrate technology exclusively licensed by the company.

The intellectual property — No. 2007-504009 — relates to the Dicer-substrate compositions for reducing mammalian target gene expression, regardless of their specific sequence, the company said.

The application stems from the work of City of Hope researcher John Rossi.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.